Skip to content
ChickenStockChickenStock
ResearchPTGX
Protagonist Therapeutics logo

Protagonist Therapeutics (PTGX) stock

NASDAQ

$130.85-2.63%(-3.53)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

24.80x

P/B

7.84x

P/S

15.46x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 5,380.0% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 6, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

17 SEC filings
  • Ali AsifChief Financial Officer · Sep 30, 2026Open-market sale58,629 shares · $8.3M
    Avg. price $141.7779
    Show 2 price lots
    • 46,034 shares × $141.78$6.5M
    • 12,595 shares × $141.77$1.8M
  • Ali AsifChief Financial Officer · Sep 30, 2026Option exercise58,629 shares · $1.4M
    Avg. price $23.7209
    Show 4 price lots
    • 28,438 shares × $23.42$666K
    • 9,229 shares × $38.98$360K
    • 15,650 shares × $19.19$300K
    • 5,312 shares × $12.17$65K
  • PATEL DINESH V PH DPresident and CEO · Sep 10, 2026Open-market sale7,278 shares · $1.0M
    Avg. price $144.1522,968 shares held after
  • PATEL DINESH V PH DPresident and CEO · Sep 10, 2026Option exercise7,278 shares · $157K
    Avg. price $21.58530,246 shares held after
  • PATEL DINESH V PH DPresident and CEO · Sep 9, 2026Open-market sale63,548 shares · $9.3M
    Avg. price $146.18522,968 shares held after
  • PATEL DINESH V PH DPresident and CEO · Sep 9, 2026Option exercise63,548 shares · $1.4M
    Avg. price $21.58586,516 shares held after
  • PATEL DINESH V PH DPresident and CEO · Sep 8, 2026Open-market sale54,174 shares · $7.9M
    Avg. price $145.87522,968 shares held after
  • PATEL DINESH V PH DPresident and CEO · Sep 8, 2026Option exercise54,174 shares · $1.2M
    Avg. price $21.58577,142 shares held after
  • PATEL DINESH V PH DPresident and CEO · Sep 3, 2026Gift510 shares · $0
    Avg. price $0522,968 shares held after
  • PATEL DINESH V PH DPresident and CEO · Aug 11, 2026Open-market sale34,239 shares · $5.1M
    Avg. price $148.52523,478 shares held after
  • PATEL DINESH V PH DPresident and CEO · Aug 11, 2026Option exercise34,239 shares · $739K
    Avg. price $21.58557,717 shares held after
  • PATEL DINESH V PH DPresident and CEO · Aug 10, 2026Open-market sale65,761 shares · $9.8M
    Avg. price $149.11523,478 shares held after
  • PATEL DINESH V PH DPresident and CEO · Aug 10, 2026Option exercise65,761 shares · $1.4M
    Avg. price $21.58589,239 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Protagonist Therapeutics (PTGX) stock information

NASDAQ

Protagonist Therapeutics (PTGX) is listed on NASDAQ. Its market capitalization is about $8.5B. On trailing-twelve-month earnings the P/E ratio is 24.8, and the P/B ratio is 7.84. Return on equity is 31.6%. These figures are computed in-house from official filings and are reference information only.

Protagonist Therapeutics — frequently asked questions

What is the P/E ratio of Protagonist Therapeutics (PTGX)?
On a trailing-twelve-month basis, PTGX trades at a P/E ratio of 24.8. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Protagonist Therapeutics?
PTGX has a market capitalization of about $8.5B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.